MARCHETTI, ANDREA
 Distribuzione geografica
Continente #
NA - Nord America 299
EU - Europa 288
AS - Asia 175
AF - Africa 32
Totale 794
Nazione #
US - Stati Uniti d'America 296
SG - Singapore 124
IT - Italia 102
SE - Svezia 61
CI - Costa d'Avorio 29
IE - Irlanda 27
IN - India 22
CH - Svizzera 20
DE - Germania 19
JO - Giordania 16
FI - Finlandia 14
BG - Bulgaria 13
GB - Regno Unito 11
CN - Cina 7
NL - Olanda 6
RU - Federazione Russa 5
FR - Francia 4
CA - Canada 3
TG - Togo 3
AT - Austria 2
HK - Hong Kong 2
JP - Giappone 2
PK - Pakistan 2
PL - Polonia 2
ES - Italia 1
LV - Lettonia 1
Totale 794
Città #
Singapore 116
Chandler 36
Abidjan 29
Dublin 27
Bologna 23
Santa Clara 20
Bern 19
Ashburn 17
Amman 16
Sofia 13
Helsinki 11
Turin 11
Fairfield 8
Princeton 8
Southend 8
Hyderabad 6
Rome 6
Redmond 5
San Polo di Torrile 5
Berlin 4
Boardman 4
Boydton 4
Florence 4
Milan 4
Rimini 4
Bühl 3
Cambridge 3
Columbus 3
Enschede 3
Lappeenranta 3
Lomé 3
Paris 3
San Diego 3
Telgate 3
Amsterdam 2
Ann Arbor 2
Deiva Marina 2
Gatineau 2
Genoa 2
Gujrat 2
Hong Kong 2
Knivsta 2
Legnano 2
Moscow 2
Norwalk 2
Seattle 2
Slough 2
Tokyo 2
Verona 2
Warsaw 2
Bangalore 1
Bari 1
Beijing 1
Cedar Knolls 1
Des Moines 1
Fort Worth 1
Houston 1
Leicester 1
Los Angeles 1
Lugano 1
New York 1
Oderzo 1
Padova 1
Pamplona 1
Redwood City 1
Riga 1
Shijiazhuang 1
Toronto 1
Trento 1
Vienna 1
Washington 1
Woodbridge 1
Totale 489
Nome #
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 65
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 58
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 43
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials 43
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 39
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 37
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 33
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 31
Bone targeting agents in patients with metastatic prostate cancer: State of the art 30
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 28
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 26
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma 26
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 25
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 22
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 22
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials 22
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 21
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer 21
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 20
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 20
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 19
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 18
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 17
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 17
Current androgen receptor antagonists under investigation for resistant prostate cancer 16
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma 15
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 13
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 12
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 12
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence 11
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 11
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma 11
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 9
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 9
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study 9
Prostate cancer and novel pharmacological treatment options - what's new for 2022? 9
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? 7
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 7
Clinical outcomes and prognostic factors in patients with penile carcinoma: a sub-analysis from Meet-URO 23 (I-RARE) registry study 5
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study 5
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 4
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial 2
Totale 870
Categoria #
all - tutte 4.409
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.409


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 7 0 5
2021/202282 0 0 1 3 2 1 6 20 5 3 29 12
2022/2023341 4 14 7 15 34 32 20 17 90 9 55 44
2023/2024218 19 36 20 14 18 27 6 16 15 12 21 14
2024/2025217 61 137 19 0 0 0 0 0 0 0 0 0
Totale 870